Sell Rating for Esperion Amidst US Market Underperformance and Competitive Pressures
PremiumRatingsSell Rating for Esperion Amidst US Market Underperformance and Competitive Pressures
1M ago
Esperion Therapeutics Reports Strong Revenue Growth in 2024
Premium
Company Announcements
Esperion Therapeutics Reports Strong Revenue Growth in 2024
1M ago
Esperion Therapeutics’ Earnings Call: Growth Amid Challenges
Premium
Company Announcements
Esperion Therapeutics’ Earnings Call: Growth Amid Challenges
1M ago
Esperion’s Strategic Expansion and Growth Potential: Analyst Recommends Buy Rating
PremiumRatingsEsperion’s Strategic Expansion and Growth Potential: Analyst Recommends Buy Rating
1M ago
Esperion partners with CSL Seqirus to commercialize NEXLETOL, NEXLIZET
Premium
The Fly
Esperion partners with CSL Seqirus to commercialize NEXLETOL, NEXLIZET
1M ago
ESPR Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ESPR Earnings this Week: How Will it Perform?
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100